Jennifer Martin, APRN
Family · Wichita, KSNPI 1124741707
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,012 of the $8,131 with a category attached, or 73.9%. It is spread thinly across 32 manufacturers, the largest accounting for just 20.0%. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Medtronic$1K
- Lilly USA, LLC$784
- Novo Nordisk$722
- Dexcom, Inc.$486
- Bayer$424
- plus $3K from 26 others
What the payments were for
- Travel & lodging$2,11826%
- Food & beverage$6,01274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 5 | $1,629 |
| Medtronic | 14 | $1,238 |
| Lilly USA, LLC | 48 | $784 |
| Novo Nordisk | 49 | $722 |
| Dexcom, Inc. | 31 | $486 |
| Bayer | 25 | $424 |
| AbbVie | 28 | $369 |
| Insulet Corporation | 41 | $367 |
| Corcept Therapeutics | 24 | $342 |
| Novartis | 23 | $301 |
| Amgen | 13 | $225 |
| AstraZeneca(2 entities) | 6 | $209 |
| Recordati_rare_diseases_inc. | 6 | $124 |
| Xeris Pharmaceuticals, Inc. | 7 | $124 |
| Astellas Pharma US Inc | 7 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $100 |
| Amneal Pharmaceuticals LLC | 5 | $83 |
| Ascensia Diabetes Care US Inc. | 4 | $74 |
| Radius Health, Inc. | 3 | $71 |
| Chiesi USA, Inc. | 3 | $48 |
| IBSA Pharma Inc. | 3 | $43 |
| Cequr Corporation | 1 | $40 |
| Antares Pharma, Inc. | 2 | $35 |
| Nevro Corp. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $26 |
| Globus Medical | 1 | $21 |
| Almatica Pharma LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$1,515
- MINIMED 780G$875
- AIRSUPRA$123
- Kerendia$108
How this compares
$8,131 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 189 | $269,138 |
| MounjaroTirzepatide | 165 | $211,141 |
| JardianceEmpagliflozin | 143 | $153,228 |
| TrulicityDulaglutide | 56 | $65,134 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $63,507 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $43,921 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $35,149 |
| FarxigaDapagliflozin Propanediol | 29 | $33,600 |
| JanuviaSitagliptin Phosphate | 24 | $26,452 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $23,452 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $21,647 |
| RybelsusSemaglutide | 12 | $21,595 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $18,680 |
| Novolog FlexpenInsulin Aspart | 48 | $18,507 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 49 | $14,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $722 | $299,139215 claims |
| Lilly USA, LLCMounjaro, Trulicity | $784 | $276,276221 claims |
| AstraZenecaFarxiga | $209 | $33,60029 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $100 | $14,37915 claims |
| AbbVieSynthroid | $369 | $7,10274 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $83 | $2,423257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
- Zohra HussainiKansas City$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.